Építés alatt – nem éles oldal
Belépés

NCT07391137Fut, nem toboroz

CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC

The Effects of a Dietary Regimen Characterized by High Consumption of Cruciferous Vegetables on Recurrence-free Survival in Patients With Intermediate, High and Very High-risk Non-Muscle Invasive Bladder Cancer: a Randomized Trial

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. febr. 9.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids [10-13]. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC [14,15]. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase [16]. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis [17-22]. Aims Primary Objective • To evaluate the effect, in terms of recurrence-free survival (RFS) at 1 year, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, or Very High-grade Non-Muscle Invasive Bladder Cancer treated with BCG (defined as the standard of care - SOC). Secondary Objectives * To evaluate the effect, in terms of time to recurrence, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer. * To evaluate the effect, in terms of recurrence-free survival (RFS), of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer with prior recurrence ≤1/yr and <4 tumors (according to 2016 EORTC risk stratification for patients treated with maintenance BCG). * To evaluate the impact of high Cruciferous vegetable consumption on urinary ITC levels. * To evaluate the impact of high Cruciferous vegetable consumption on quality of life (QoL).

Állapot (regiszter)
Fut, nem toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
250 (tervezett)
Első benyújtás
2025. ápr. 15.
Kezdés
2025. okt. 17.
Elsődleges befejezés
2026. nov. 1.
Fő szponzor
S. Andrea Hospital
Betegségek
Hólyagrák
NCT-szám
NCT07391137

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 250
  • 2025. okt. 17. és az elsődleges befejezés (2026. nov. 1.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Concomitant Urothelial Bladder Cancer in the Upper-Urinary Tract
  • Prostate or bladder radiotherapy
  • Warfarin therapy

Más betegség

  • Low-Risk Non-Muscle Invasive Bladder Cancer
  • Muscle Invasive Bladder Cancer
  • Urinary tract infection
  • Other ongoing oncological diseases
  • Persistent disease (defined as residual disease detected within three months after TURB or at first cystoscopy)
  • Specific dietary restrictions such as a vegetarian diet, celiac disease, or lactose intolerance
  • Chronic Kidney Disease
  • Chronic inflammatory diseases such as Crohn's disease or ulcerative colitis
  • History of gastric resection
  • Thyroid disorders

Laborértékek

  • Hepatic disorders such as cirrhosis or ALT/AST levels three times above the upper normal limit

Életkor

  • Life expectancy < 5 years

Egyéb

  • WHO performance status 3 or 4
  • Variant histology
  • Chronic urinary retention or indwelling catheters
  • Active oncological treatments in the past 12 months

Kiket keres a vizsgálat

  • Histologically confirmed Non-Muscle Invasive Bladder Cancer of Intermediate, High, or Very High risk according to the 2021 EAU NMIBC scoring model.
  • Age ≥ 18

Életkor a regiszterben: 18 év – 75 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
S.Andrea Hospital of RomeRomeOlaszországIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.